Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record.

Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up

Open access
KOHN, A., DAPERNO, M., ARMUZZI, A., CAPPELLO, M., BIANCONE, L., ORLANDO, A., VISCIDO, A., ANNESE, V., RIEGLER, G., MEUCCI, G., MARROLLO, M., SOSTEGNI, R., GASBARRINI, A., PERALTA, S., PRANTERA, C.·2007·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Severe ulcerative colitis is a life‐threatening disorder, despite i.v. glucocorticoids treatment. Infliximab has been proposed as a safe rescue therapy. Aim: To evaluate short‐ and long‐term effectiveness and safety of infliximab in severe refractory ulcerative colitis. Methods: Eighty‐three patients with severe ulcerative colitis (i.v. glucocorticoids treatment‐refractory) were treated with infliximab in 10 Italian Gastroenterology Units. Patients underwent one or more infusions according to the choice of treating physicians. Short‐term outcome was colectomy/death 2 months after the first infusion. Long‐term outcome was survival free from colectomy. Safety data were recorded. Results: Twelve patients (15%) underwent colectomy within 2 months. One died of Legionella pneumophila infection 12 days after infliximab. Early colectomy rates were higher in patients receiving one infusion (9/26), compared with those receiving two/more infusions (3/57, P = 0.001, OR = 9.53). Seventy patients who survived colectomy and did not experience any fatal complications were followed‐up for a median time of 23 months; 58 patients avoided colectomy during the follow‐up. Forty‐two patients were maintained on immunosuppressive drugs. No clinical features were associated with outcomes. Conclusions: Infliximab is an effective and relatively safe therapy to avoid colectomy and maintain long‐term remission for patients with severe refractory ulcerative colitis. In the short term, two or more infusions seem to be more effective than one single infusion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2007.03415.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 168

Metadata

Authors
KOHN, A., DAPERNO, M., ARMUZZI, A., CAPPELLO, M., BIANCONE, L., ORLANDO, A., VISCIDO, A., ANNESE, V., RIEGLER, G., MEUCCI, G., MARROLLO, M., SOSTEGNI, R., GASBARRINI, A., PERALTA, S., & PRANTERA, C.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2007-06-21
Volume
26
Issue
5
Pages
747-756
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1565354477
Cited by
168
References
0
FWCI
8.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up. https://app.cochat.ai/papers/10.1111/j.1365-2036.2007.03415.x
The paper
KOHN, A., DAPERNO, M., ARMUZZI, A., CAPPELLO, M., BIANCONE, L., ORLANDO, A., VISCIDO, A., ANNESE, V., RIEGLER, G., MEUCCI, G., MARROLLO, M., SOSTEGNI, R., GASBARRINI, A., PERALTA, S., & PRANTERA, C. (2007). Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2007.03415.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.